tbuckley/cabot-search huggingface dataset:
SUFFUSION OF SUFFIXES
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Prognosis
Authors: Amy L. Gleberman
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
General References
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase 1b study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer.
Authors: Kimberly Perez, Douglas Adam Rubinson, James M. Cleary, Jeffrey A. Meyerhardt, Anuj K. Patel, Thomas Adam Abrams, Osama E. Rahma, Srivatsan Raghavan, Andrew Aguirre, Michael N. Needle, Koushik Das, Jason Pitarresi, Basil Bakir, Anil K. Rustgi, Brian M. Wolpin
Journal: Journal of Clinical Oncology (2018)

TPS4152 Background: Nearly 80% of patients diagnosed with pancreatic ductal adenocarcinoma(PDAC) present with advanced, unresectable disease at the time of diagnosis, and as a result only about 4% will live 5 years after diagnosis. Paired-related homeodomain transcription factor 1 (Prrx1) isoforms – Prrx1a and 1b - are involved in pancreatic development, pancreatitis, and carcinogenesis. Prrx1a stimulates metastatic outgrowth and mesenchymal-epithelial transition(MET). Prrx1b promotes invasion and epithelial-mesenchymal transition (EMT). HGF is a novel transcriptional target of Prrx1b. Ficlatuzumab is a potent and selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody. It neutralizes HGF/c-Met binding and HGF-induced c-Met phosphorylation thereby inhibiting the c-Met pathway which has been associated with progression from primary to metastatic disease. In preclinical pancreatic adenocarcinoma models, inhibition of Prrx1b-HGF signaling using ficlatuzumab in combination with gemcitabine reduced primary tumor volume and eliminated metastatic disease. Methods: Patients with untreated metastatic PDAC will be enrolled in a phase Ib dose escalation study with 3+3 design and three dose cohorts of ficlatuzumab administered with gemcitabine (1000 mg/m2) and nab-paclitaxel (125 mg/m2) given 3 weeks on and 1 week off, followed by 18 patient expansion phase at maximally tolerated dose (MTD) for safety evaluation. The primary objective is to identify the MTD of ficlatuzumab when administered in combination with gemcitabine and nab-paclitaxel in patients with previously-untreated advanced pancreatic cancer. Secondary objectives include evaluation of safety, response rate and progression-free survival. Exploratory objectives will be performed to evaluate serum and tumor biomarkers of disease response. This analysis will include evaluation of a BDX004 prognostic proteomic signature detected in patients’ pre-treatment blood sample. A pre-treatment biopsy will also be interrogated for HGF and markers of the cMet pathway; by immunohistochemistry, exome and transcriptome sequencing, and organoid development. Clinical trial information: NCT03316599.
Quality and quantity in medical education
Authors: H. R. Mason
Journal: JAMA (1971)

About 60 years ago, there was published bulletin 4 of the Carnegie Foundation for the Advancement of Teaching entitled<i>Medical Education in the United States and Canada</i>. This book by Abraham Flexner, which came to be known as the "Flexner Report," described a study of the medical schools in the United States and Canada by the Carnegie Foundation, a study for which the American Medical Association was largely responsible. This report was followed by tremendous changes in medical education, to the great benefit of the public. These changes recognized primarily the need for medical practitioners to have substantial grounding in the biomedical sciences. Eventually, the quality of medical schools in the United States and Canada reached a level which, with respect to both the advancement of medical science and the training of physicians, is not exceeded, if indeed equalled, any place in the world. While the ascendancy of the Flexner
Grandma
Authors: Thomas L. Petty
Journal: JAMA (1984)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial
Authors: J. O'Shaughnessy, C. Osborne, J. Pippen, M. Yoffe, D. Patt, G. Monaghan, C. Rocha, V. Ossovskaya, B. Sherman, C. Bradley
Journal: Journal of Clinical Oncology (2009)

3 Background: TNBC is an aggressive breast cancer subtype that shares molecular and pathologic features with BRCA1-related breast cancers. BRCA-deficient cells are sensitive to inhibition of PARP1, a critical enzyme of cell proliferation and DNA repair, and thus represent a rational target of PARP inhibitor-based cancer therapy. The objectives of this study were to evaluate BSI-201, a potent PARP1 inhibitor, in combination with gemcitabine/carboplatin (G/C) in subjects with metastatic TNBC. Methods: Eligible subjects had measurable disease and had ≤2 prior cytotoxic regimens for ER-, PR-, and HER2-negative metastatic breast cancer. Patients were randomized (1:1) to G/C alone or G/C + BSI-201. Gemcitabine (1000 mg/m 2 ) and carboplatin (AUC=2) were given on days 1 and 8, and BSI-201 (5.6 mg/kg; iv; biweekly) on days 1, 4, 8, and 11 every 21 days. Endpoints were clinical benefit rate (CBR = CR + PR + SD ≥6 months), progression-free survival (PFS) and overall survival (OS). Results: Analyses of the first 86 of a planned 120 patients showed that BSI-201 + G/C had improved CBR, median PFS, and median OS, compared with G/C alone. The frequency and nature of adverse events (AEs) did not differ between arms. Conclusions: This preliminary analysis demonstrates that BSI-201 + G/C significantly improves CBR, PFS, and OS, compared with G/C alone. BSI-201 + G/C was well tolerated, with BSI-201 adding no significant toxicity to G/C. Updated CBR, PFS, and OS for all 120 patients and exploratory correlative analyses of PARP expression and clinical response will be presented. [Table: see text] [Table: see text]
Rapid Technique for Obtaining Leukocytes from Small Blood Samples
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Human Cell Exposure Assays of Bacillus thuringiensis Commercial Insecticides: Production of Bacillus cereus-Like Cytolytic Effects from Outgrowth of Spores
Authors: Azam F. Tayabali, Verner L. Seligy
Journal: Environmental Health Perspectives (2000)

Most contemporary bioinsecticides are derived from scaled-up cultures of Bacillus thuringiensis subspecies israelensis (Bti) and kurstaki (Btk), whose particulate fractions contain mostly B. thuringiensis spores (> 10(12)/L) and proteinaceous aggregates, including crystal-like parasporal inclusion bodies (PIB). Based on concerns over relatedness to B. cereus-group pathogens, we conducted extensive testing of B. thuringiensis (BT) products and their subfractions using seven human cell types. The Bti/Btk products generated nonspecific cytotoxicities involving loss in bioreduction, cell rounding, blebbing and detachment, degradation of immunodetectable proteins, and cytolysis. Their threshold dose (Dt approximately equal.5 times 10(-14)% BT product/target cell) equated to a single spore and a target cell half-life (tLD(50)) of approximately 16 hr. At Dts > 10(4), the tLD(50) rapidly shifted to < 4 hr; with antibiotic present, no component, including PIB-related [delta]-endotoxins, was cytolytic up to an equivalent of approximately 10(9 )Dt. The cytolytic agent(s) within the Bti/Btk-vegetative cell exoprotein (VCP) pool is an early spore outgrowth product identical to that of B. cereus and acting possibly by arresting protein synthesis. No cytolytic effects were seen with VCP from B. subtilis and Escherichia coli. These data, including recent epidemiologic work indicate that spore-containing BT products have an inherent capacity to lyse human cells in free and interactive forms and may also act as immune sensitizers. To critically impact at the whole body level, the exposure outcome would have to be an uncontrolled infection arising from intake of Btk/Bti spores. For humans, such a condition would be rare, arising possibly in equally rare exposure scenarios involving large doses of spores and individuals with weak or impaired microbe-clearance capacities and/or immune response systems.
Abstract 21311: A Novel, Shear-Assembling, Shear-Thinning Polymer-Nanoparticle Hydrogel Diminishes Post-Operative Thoracic Adhesions in a Rodent Model of Ischemic Cardiomyopathy
Authors: Lyndsay M Stapleton, Amanda N Steele, Akshara D Thakore, Andrew B Goldstone, Vi N Truong, Anahita Eskandari, Mike J Paulsen, Alexandra T Bourdillon, Anthony C Yu, Masashi Kawamura, Kevin J Jaatinen, Justin M Farry, Eric A Appel, Y J Woo
Journal: Circulation (2017)

Objective: The incidence of post-operative adhesions is estimated to be 93%, resulting in severe pain, bowel obstruction, infertility, and often requires re-operation. Mainstay adhesion prevention technologies are generally derived from polymer films that serve as physical barriers between scarring tissue and surrounding organs. Yet, these films have not been widely accepted due to their inability to adequately limit adhesions and difficulty handling during surgery. We hypothesized shear-thinning, self-healing polymer nanoparticle hydrogels (PNP) would instead provide a novel, viscoelastic barrier between tissues and organs, allowing tissues to move past each other similar to the body’s natural state, effectively preventing adhesion formation (Fig. 1A). Methods: PNP shear-thinning and self-healing behavior was characterized via rheometry. Adult male Sprague Dawley rats (n=23) underwent sham surgery or permanent ligation of the LAD followed by pericardial application of 250μL PNP gel, 1cm 2 Interceed®--a commercially available adhesion barrier, or no treatment. Degree of adhesion formation, cardiac function, infarct size, and immune response were assessed 4-weeks post infarction. Results: PNP exhibited fast, complete recovery of mechanical properties following network rupture at high strains indicating the reversible and robust nature of the hydrogel system. (Fig. 1B). Infarct size and ejection fraction were controlled to ensure similar inflammatory responses contributing to adhesion formation across treatment groups (1C and D). Treatment with PNP significantly reduced the development of adhesions compared to Interceed and untreated controls (Fig. 1E). Conclusion: Administration of a shear-thinning, self-healing hydrogel reduces the extent of adhesion formation in the thoracic cavity following a thoracotomy and myocardial infarction. PNP provides an easily delivered, scalable solution for post-operative adhesion prevention.
Reduction in hepatitis B virus quasispecies during lamivudine treatment is associated with enhanced virus replication and hepatocytolysis 1Institute of Liver Studies, King's College Hospital, London, UK; 2Ochsner Clinic, New Orleans, LA; 3Massachusetts General Hospital, Boston, MA; 4Glaxo Research Institute, Research Triangle Park, NC, U.S.A.
Journal: Hepatology (1995)

We recently found that phosphatidyl-2′,3′-dideoxycytidine (phosphatidyl-ddC) had substantial anti-hepatitis B virus (HBV) activity in vitro compared to 2′,3′-dideoxycytidine (ddC) (Hostetler et al. (1994) Antiviral Res. 24, 59–67). Upon administration of liposomal phosphatidyl-ddC to mice, a 40-fold higher drug area under curve was observed in the liver. To evaluate the possibility of using liver-targeted anti-HBV nucleosides to treat woodchuck hepatitis virus, we wanted to find the most potent and selective lipid conjugates. It has been shown that 2′,3′-dideoxy-3′-thiacytidine as a racemic mixture of the cis-isomer (cis-(±)-BCH-189) has much greater activity against HBV viruses than ddC in vitro. Recently, it was shown that the (−)-β-l-enantiomer (3TC) is more active and less toxic than the (+)-β-d-form ((+)-BCH-189). To determine whether phospholipid conjugates of 3TC retain antiviral activity in 2.2.15 cells as demonstrated previously with ddC, we synthesized the 1,2-dipalmitoyl-sn-glycerol-3-phosphate conjugates of (±)-BCH-189 and 3TC and assessed their anti-HBV and anti-HIV activities, in vitro. Phosphatidyl-3TC and phosphatidyl-BCH-189 had antiviral activity comparable to the respective free drugs in 2.2.15 cells which chronically produce HBV. In HIV-1-infected human peripheral blood mononuclear cells and HT4-6C cells, phosphatidyl-3TC and phosphatidyl-(±)-BCH-189 exhibited significantly lower activity than the corresponding free nucleosides. In view of the documented ability of phosphatidyl-ddC to target drug to the liver, it seems reasonable to expect that phosphatidyl-3TC or phosphatidyl-(±)-BCH-189 could be employed to provide greatly enhanced hepatic antiviral activity in HBV infection in vivo.
The spleen.
Authors: Lester S. King
Journal: JAMA (1963)

Every book must justify its existence. Why was it written? What purpose does it serve? To what audience is it directed? In the present case the editor, who is also the principal author, notes the great amount of newer knowledge of structure and function of the spleen and hopes that his book will be a "useful reference for the physician." Approximately two thirds of the volume is devoted to the chapter, "Pathology of the Spleen." The general arrangement of topics and the numerous excellent illustrations, predominantly photomicrographs, strongly suggest that this portion represents the substance of lectures to medical students in pathology. The mode of presentation is quite similar to what can be found in the larger current textbooks of pathology, but is given here in considerably more detail. Intermingled with the morphologic details are discussions of pathogenetic mechanisms. The remainder of the book includes four other chapters, each relatively
Dissecting Aneurysm
Authors: A. Shimizu
Journal: JAMA (1974)

<h3>To the Editor.—</h3> We have a patient who has been dependent on dialysis for the past six years and who survived an aortic dissection some 2 1/2 years ago, like that reported by Chiorazzi et al (228:1146, 1974). This patient, now 37 years of age, was first seen in 1968, at which time he was found to have terminal renal failure with a serum creatinine clearance of 18.2 mg/100 ml. His primary diagnosis was chronic glomerulonephritis. It was believed that since he had malignant hypertension, his renal function had deteriorated more rapidly than the natural course of the chronic glomerulonephritis. His blood pressure at that time was 230/150 mm Hg and his fundi showed large amounts of exudates, hemorrhages, and papilledema, bilaterally. Neurological examination at this time was normal. Because he was a Jehovah's Witness (at that time we were still giving blood intermittently to hemodialysis patients), he was given
American Journal of Digestive Diseases and Nutrition
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Such Promise
Authors: Haley Newman
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Impaired Expression of p66Shc, a Novel Regulator of B-Cell Survival, in Chronic Lymphocytic Leukemia.
Authors: Cosima T. Baldari, Nagaja Capitani, Orso Maria Lucherini, Elisa Sozzi, Micol Ferro, Nico Giommoni, Francesca Finetti, Giulia De Falco, Emanuele Cencini, Pier Guiseppe Pelicci, Francesco Lauria, Francesco Forconi
Journal: Blood (2009)